엑소시스템즈
3 known investors
Exosystems develops AI-based digital biomarkers for the assessment, monitoring, and treatment of neuromuscular and musculoskeletal disorders, supporting diagnosis, severity assessment, and disease progression tracking for conditions such as stroke, Parkinson's, ALS, SMA, sarcopenia, and myasthenia gravis. Its technology aims to provide faster, non-invasive, and reproducible quantitative neuromuscular evaluations for clinical and healthcare settings.
Also known as (주)엑소시스템즈 · exosystems · EXOSYSTEMS Inc. · 엑소시스템즈
Investors · 3
Also in the syndicate · 1
Company profile
researched Aug 2026EXOSYSTEMS Inc. (엑소시스템즈) is a South Korean digital healthcare company that develops AI-based digital biomarkers for the assessment, monitoring and treatment of neuromuscular and musculoskeletal (MSK) disorders. Its stated product areas span central and peripheral nervous system digital biomarkers used for severity assessment in stroke, Parkinson's disease, ALS and SMA; diagnostic support for sarcopenia and myasthenia gravis; and quantitative neuromuscular assessment. The company positions its measurement workflow as an approximately three-minute, non-invasive evaluation intended to reduce labor-intensive procedures, extend testing to patients with limited mobility, and reduce examiner-dependent variability through standardized quantitative metrics.
The product portfolio is organized into medical and wellness lines. Medical offerings include sarcopenia diagnostic support, dynamic electromyography (EMG), remote therapeutic monitoring (RTM), personalized electroceuticals and personalized digital therapeutics (DTx). Wellness offerings include a personalized musculoskeletal home-care solution and a data-driven fitness solution, marketed under the exoFit name. Earlier product coverage describes exoRehab, a smart knee health management solution pairing a wearable rehabilitation medical device with a tablet application containing training programs, electrical stimulation for muscle growth, personalized feedback and health-data management. The company is registered under manufacturing of electrical diagnostic and therapeutic apparatus, electronic sensing devices and fitness equipment, plus e-commerce and application software development.
The company is a spin-off from ETRI (Electronics and Telecommunications Research Institute), incorporated in January 2017 and led by CEO 이후만 (Lee Hu-man). It is headquartered in the Pangyo Global Biz Center in Sujeong-gu, Seongnam, Gyeonggi Province, South Korea.
Founding story
The company began as a spin-off from ETRI (Electronics and Telecommunications Research Institute) and was established to address gaps in healthcare access in an aging society, framing the problem as the labor-intensive, location-dependent structure of professional health services rather than distance to providers alone. It was incorporated on 2017-01-04 (registry filings also cite 2017-01-06) and is led by CEO 이후만.
Business model
The company designs and manufactures wearable medical devices paired with software — user apps, digital therapeutics and analytics — sold into clinical and healthcare settings, and also offers wellness/home-care and fitness versions of the same digital-biomarker technology. Regulatory clearances (Korean MFDS device approval, European CE-MDD) are described as the basis for commercialization, and government R&D programs have supplied additional funding.
Revenue derives from device and software solutions across medical diagnostic/monitoring, treatment and wellness lines, supplemented by government-funded R&D projects. Reported revenue was KRW 1.411bn in FY2025, up 185% year over year, against an operating loss of KRW 304m and a net loss of KRW 454m.
Traction
Revenue grew from KRW 79m (2022) to KRW 321m (2023), KRW 495m (2024) and KRW 1.411bn (2025). The company reported clinical research with major Korean medical institutions, Korean MFDS device approval and European CE-MDD clearance, selection as lead operator of government R&D projects worth about KRW 6bn from the Korea Medical Device Development Fund and the Ministry of Trade, Industry and Energy, innovative medical device designation for its AI sarcopenia diagnostic support (2024-11), publication of its AI digital biomarker technology in an SCI-indexed international journal (2024-09), CES Innovation Awards in 2024 and 2026, and a Minister's Award at the Korea Invention Patent Exhibition (2023-11). Headcount was 14 as of August 2023.
Latest developments
Reported developments include a K-MEDI hub-supported CES Innovation Award alongside FAMITI (2026-01), a Daewoong Pharmaceutical smart ward collaboration with Seers Technology (2025-12), a senior-town health lecture on muscle health (2025-11), an AI-based personalized health screening program with Daewoong Pharmaceutical for North Korean defectors (2025-09), selection of K-MEDI hub for a digital biomarker international standardization base project (2025-05), and the launch of the exoFit data-driven smart training solution with Abridge (2025-04). Financially, 2025 revenue nearly tripled while the company returned to an operating and net loss.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
The company describes itself as targeting global standards for musculoskeletal disease diagnosis. Investors compared its market opportunity to US MSK digital care companies, citing Hinge Health's $300m raise as evidence of market interest, and noted that Exosystems combines both AI software and hardware capability. It ranks 87th by disclosed revenue among Korean companies classified under manufacturing of electrical diagnostic and therapeutic apparatus.
Stated differentiators are the combination of in-house AI software and wearable hardware, digital biomarker analysis linked to evidence-based behavioral intervention protocols, a short and non-invasive assessment process applicable to patients for whom conventional protocols are difficult, and standardized, reproducible metrics that reduce examiner dependence. Regulatory milestones include Korean innovative medical device designation for AI-based sarcopenia diagnostic support and CE-MDD clearance.
Technology
The core technology is AI-based digital biomarkers derived from wearable sensor data, including dynamic electromyography, covering both central and peripheral nervous system indicators. Algorithms analyze movement and muscle signals to produce quantitative severity and progression metrics in roughly a three-minute assessment, and to drive behavioral interventions such as exercise prescription, electrical stimulation and personalized digital therapeutic programs with real-time feedback.
Go-to-market
The company works through partnerships with medical and healthcare organizations to validate and scale its solutions, and has run clinical research with Korean hospitals including Seoul National University Bundang Hospital. Corporate collaborations include Daewoong Pharmaceutical (AI-based personalized health screening programs and smart ward initiatives) and Abridge for the exoFit training solution. Public-sector programs such as K-MEDI hub support and Ministry of SMEs and Startups initiatives, plus CES exhibitions and awards, are used for visibility.
Hospitals, clinicians and rehabilitation providers treating neuromuscular and musculoskeletal conditions; patients with stroke, Parkinson's, ALS, SMA, sarcopenia or myasthenia gravis, including those with limited mobility; and consumers/fitness users via home-care and training solutions.
Geography
Headquartered in Seongnam (Pangyo), Gyeonggi Province, South Korea, with domestic clinical and commercial activity and European market access via CE-MDD clearance; CES participation and stated global business ambitions.
History
Founded in January 2017 as an ETRI spin-off, the company developed the exoRehab wearable knee rehabilitation solution and obtained Korean MFDS device approval and European CE-MDD clearance. In October 2021 it raised a KRW 4.5bn Series A, bringing cumulative funding to about KRW 5bn, and around the same period was selected as lead operator of roughly KRW 6bn in national R&D programs. It won a Minister's Award at the Korea Invention Patent Exhibition in November 2023 and a 2024 CES Innovation Award for its AI digital biomarker solution. In September 2024 its digital biomarker technology was published in an SCI-indexed journal, and in November 2024 its AI-based sarcopenia diagnostic support received innovative medical device designation in Korea. In 2025 it launched the exoFit data-driven training solution with Abridge, participated in K-MEDI hub's digital biomarker international standardization project, and worked with Daewoong Pharmaceutical on AI-based health screening for North Korean defectors and on smart ward development. It received another CES Innovation Award reported in January 2026.
Risks & controversies
Financial disclosures show the company swung from an operating profit of KRW 77m in 2024 to an operating loss of KRW 304m and a net loss of KRW 454m in 2025 despite revenue growth, with industry-relative rankings placing it in the lowest bands for activity and profitability, a credit grade of "fair" (양호), and negative operating and investing cash flows in 2025. Absolute revenue remains small (KRW 1.4bn) and headcount is limited.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 12
launches, deals, and filingsDaewoong Pharmaceutical ESG program using AI-based personalized health screening involving EXOSYSTEMS.
Exosystems' AI-based sarcopenia diagnostic support solution received innovative medical device designation in Korea.
Exosystems announced a KRW 4.5bn Series A round with participation from SBI Investment, Laguna Investment and the Korea Technology Finance Corporation, bringing cumulative funding to about KRW 5bn. CEO Lee Hu-man said proceeds would go to hiring, expanding the clinical research pipeline and building a base for global business.
The company reported holding Korean Ministry of Food and Drug Safety medical device approval and European CE-MDD (Medical Devices Directive) clearance as the basis for commercialization.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- 엑소시스템즈exosystems.io · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does 엑소시스템즈 do?
- Korean medical device maker building AI digital biomarkers and wearable devices for neuromuscular and musculoskeletal care.
- Who are 엑소시스템즈's investors?
- 엑소시스템즈's investors include Kakao Ventures, Laguna Investment.